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ABSTRACT
Objective: the goal of this research has been to evaluate the
survival, in long and short term, of the patient receiving liver
transplant for hepatocellular carcinoma (HCC), the risk of post-
transplant tumor relapse and factors related to this complication. 
Design: retrospective study of a consecutive series of patients
having had liver transplant for HCC.
Patients and methodology: transplant patients for HCC from
1989 to November 2003. Patients were selected due to general lim-
itations of nodule size and quantity, which were subsequently pub-
lished as Milan criteria. Also, criteria agreed in the Conference of
Barcelona were followed in the pre-transplant diagnosis.
Results: the survival of this 81 patients group was of the 80,
61 and 52% for 1, 5 and 10 years respectively. In the 32% of the
cases the HCC was an incidental finding in the explant. In the
12.3%, the tumor relapse was verified. The multivariate research
identified the size of the nodule (OR = 1,7944) (IC 95% =
1,1332-2,8413) and the vascular invasion (OR = 6,6346) (IC
95% = 1,4624-30,1003) as risk factors of relapse.
Conclusions: the liver transplant in selected patients with HCC
has good results in medium and long term. The risk of post-trans-
plant tumor relapse becomes notably reduced and is associated with
the size of the nodule and the microscopic vascular invasion.
Key words: Hepatocellular carcinoma. Liver transplant. Inciden-
tal tumors. Survival.
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INTRODUCTION
The HCC represents more than the 5% of the diag-
nosed tumors worldwide, and it is the fifth more frequent
cancer in men and the eighth in women, causing 500.000
deaths per year (1).
The resection surgery and the liver transplant are the
only therapeutic options with healing potentiality for
HCC patients, but its applicability is very limited by the
degree of the hepatic function and the size of the tumor.
The resection surgery is the first therapeutic line but it is
meant for small sized HCC and only nodule with a pre-
served hepatic function and without portal hypertension.
In these patients, despite a careful selection, the rate of
tumor recurrence after 3 years might exceed the 50% of
the chances after 5 years (2).
With patients suffering unbalanced cirrhosis or mul-
ti-nodule HCC, the treatment to follow is the orthotrop-
ic hepatic transplant (OHT). These patients reach a sur-
vival rate of the 70% in 5 years, with a tumor
recurrence inferior to the 15% when the candidates are
selected by the Milan criteria (only nodule minor or
equal to 5 cm, or up to 3 nodules of 3 cm or less) (3,4).
The ablation of the tumor by means of percutaneous al-
coholysis or radio frequency is included within the
group of radical therapies by some authors, yet it bears
a high rate of relapse and has considerable limits for its
accessibility (5-7).
Another alternative in the treatment for HCC is the
transarterial chemoembolization (6,8), which has
proved beneficial to patients with no healing options.
This procedure can be applied in the pre-transplant peri-
od so as to prevent tumor growth, which is one of the
causes for being excluded from the wait list in the 15-
30% of the cases (9). The size and the quantity of the
nodules and the reaction to the chemoembolization have
been credited as determining risk factors of post-trans-
plant tumor growth and relapse (5,10).
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ORIGINAL PAPERS
The prognosis for HCC has been established upon the
basis of various classification systems (TNM, Okuda)
which were reviewed in the European Association for the
Study of the Liver (EASL) conference that was held in
Barcelona in 2000. This event gave special importance to
the prognostic value of the stages of tumor development,
the degree of affectation of the hepatic function, the gen-
eral state of the patient and the effectiveness of the treat-
ment. These four variants are included in the current tu-
mor phasing methods such as the Cancer of the Liver
Italian Program (CLIP), which combines four variants
and offers a seven-stage classification system; and the
Barcelona Clinic Liver Cancer (BCLC), which also uses
four variants but distinguishes only four stages in the tu-
mor development (4).
We have retrospectively reviewed the results obtained
from a wide group of patients who received a liver trans-
plant for HCC in order to analyze their survival in long
term and the factors that determine the risk of tumor re-
lapse after the transplant. 
PATIENTS AND METHODS
Patients
The sample for this retrospective study has been trans-
plant patients for HCC from 1989 to 2003. Transplant in-
dications for patients with HCC were strictly adapted to
the Milan criteria since 1996 (11). Between 1989 and
1996 the selection of candidates had been made accord-
ing to very similar limits, taken because of the generality
of the transplant units (12). There were some cases in
which a patient was excluded from the selection: if the
tumor had a size bigger than 6 cm; if there were 4 or
more than 4 nodules; and those patients with signs of vas-
cular invasion or extrahepatic dissemination (3,4). Ever
since 1996 only three patients with tumors of 5-6 cm
were accepted in a wait list, having previously passed a
chemoembolization session, which managed to get the
tumor size reduced. For this research we have included
those patients with histological diagnosis of HCC in the
hepatic explant, unknown before the transplant (inciden-
tal HCC). 
Diagnosis
The diagnosis of HCC follows the recommendations
agreed in the conference about HCC that took place in
Barcelona in 2000 (4), which unite histological criteria,
high level of alphaphetoprotein and image techniques.
Before including the patient in a wait list, an exhaus-
tive extension study (Doppler ecography, thoracic TC
and bone gammagraphy) must be made so as to discard
extrahepatic dissemination. 
Analyzed variants and statistic analysis
The variants analyzed in this study are the following:
age, sex, etiology of hepatopathy (C-virus, B-virus, alco-
hol and others), number of nodules, size of the biggest
nodule (in the surgical piece), microscopic signs of inva-
sion (vascular, capsular and lymphatic), tumor differenti-
ation, patient death, cause of the death, time of develop-
ment, tumor relapse and incidental tumor.
In this research a descriptive analysis of the series has
been carried out. Student’s T and Fisher’s test have also
been used. The analysis of the survival has been made ac-
cording to Kaplan-Meier’s method. Lastly, a univariate
and multivariate logistic regression analysis has been
performed in order to obtain the risk factors associated to
post-transplant relapse. The research has been achieved
using the statistics software SPSS version 8.1.
RESULTS
Descriptive analysis
Between 1989 and November 2003, 585 orthotopic
liver transplants have been performed. Eighty one of
them (13,8%) were for patients with grafted HCC. In 55
of those patients (67,9%) the tumor had been diagnosed
before the transplant and confirmed in the explant. In the
26 remaining patients (32,1%) the HCC was found after
the histopathological study (incidental HCC). Nine pa-
tients were women (11,1%) and 72 were men (88,9%).
The average age was 53,8 ± 8,6 with a range from 22 to
68 years old. The most relevant results from this group
are exposed in table I.
The most frequent etiology for cirrhosis  was the He-
patitis C virus (HCV), with a whole of 41 patients
(50,6%), followed by the alcohol (14 patients; 17,3%),
then the hepatitis B virus (HBV) (9 patients; 11,1%) and
lastly other less frequent causes (17 patients; 20,1%).
In 10 patients (12,3%) tumor relapse occurred. Twenty
eight from the 81 patients group (34,6%) passed away, 9
cases (32,1%) due to tumor relapse. One patient with
HCC relapse still lives nowadays. Six patients died be-
cause of viral relapse (21,4%), four by sepsis (14,3%),
and the rest by other causes such as primary graft dys-
function, chronic rejection, multiorganic failure, sudden
death, myocardial infarction, cerebral hemorrhage, diges-
tive hemorrhage due to varices and suicide.
Analysis of survival
The survival of this group of patients was of the 80%
the first year after the transplant was performed. In the
next years there would be a progressive decrease of this
percentage, coming down to the 61% for 5 years and 52%
for 10 (Fig. 1). The development of the patients with inci-
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dental HCC was worse than those who had the HCC di-
agnosed before the transplant, with an average survival of
5 ± 1,18 and 7 ± 1,35 years respectively (p = 0,0386), but
this factor turned out to have no statistic significance in
the multivariate analysis. 
Patients who experienced tumor relapse had a clearly
unfavorable development and most of them passed away
during the first three years after the transplant (Log-Rank
p < 0.05) (Fig. 2).
Univariate analysis
The univariate analysis of the risk factors of tumor re-
lapse after transplant gave statistic significance to the
vascular invasion, the size of the biggest nodule and the
degree of histological differentiation. The lymphatic in-
vasion reached only marginal significance but it was in-
cluded in the multivariate study. 
In relation to the degree of differentiation, it is appreci-
ated that a pronounced decrease of the survival occurs
when the tumors are poorly differentiated, with an aver-
age survival of 9 ± 1,28 years in the well differentiated
tumors, 6,83 ± 0,73 years in the moderately differentiated
ones, and 1,3 ± 0,68 years in the poorly differentiated
ones (p = 0,0107).
Patients with vascular invasion had higher rate of re-
lapse (p = 0,007), which explains their low rate of sur-
vival.
The size of the nodule has also proved its statistic sig-
nificance. According to Student’s test, the risk of relapse
was higher in patients with bigger tumors (p = 0,001)
(Table II).
Multivariate analysis
The multivariate study by means of logistic regres-
sion (considering the post-transplant relapse of HCC as
a dependent variable) identified the size of the nodule
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Table I. Descriptive data of the sample
Variables n Percentage
Incidental
Yes 26 32.1
No 55 67.9
Vascular invasion
Yes 19 23.5
No 62 76.5
Capsular invasion
Yes 6 7.4
No 75 92.6
Lymphatic invasion
Yes 5 6.2
No 76 93.8
Differentiation
Good 30 37
Mild 48 59.3
Poor 3 3.7
Recurrence
Yes 10 12.3
No 71 87.7
Deaths
Yes 28 34.6
No 53 65.4
Uninodular 42 51.9
Multinodular 39 48.1
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Fig. 1.- General survival curve of patients.
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Fig. 2.- Survival rate according to tumor recurrence.
Superviviencia según recidiva tumoral.
Table II. Variables with statistic significance in univariate
analysis
B Significance R Exp (B)
Vascular invasion 1.9006 0.0078 0.2894 6.6901
Nodular size 0.6057 0.0092 0.2802 1.8325
Lymphatic invasion 1.7346 0.0787 0.1343 5.6666
Differentiation 2.0001 0.0160 0.2505 7.3896
(OR = 1,7944) (IC 95% = 1,1332-2,8413) and the vascular
invasion (OR = 6,6346) (IC 95% = 1,4624-30,1003) as
risk factors with independent nature (Table III). 
DISCUSSION
The HCC is the most frequent malignant tumor for the
liver and it is clearly linked to the presence of hepatic cir-
rhosis. In the last few years there has been an important
increase of its prevalence motivated by multiple factors,
such as the higher survival of patients with cirrhosis, the
development of the image techniques and the establish-
ment of monitoring programs (13).
In Europe, the 85-90% of the HCC appears upon he-
patic cirrhosis (14-16). In this group of patients the liver
transplant is the selected treatment (4). The high rates of
tumor relapse described in the initial stages (32-54%) and
the consequent low rates of survival (< 40% in 5 years)
originated a review of the transplant criteria for these pa-
tients. The size and quantity of the nodules got limited
and those cases with microscopic vascular invasion or
extrahepatic dissemination were discarded for transplant.
This clinic practice got consolidated in the so-called Mi-
lan criteria (11,17,18), which made it possible to commu-
nicate survival rates of the 70% for 5 years and percent-
ages of relapse inferior to 15% (3,4,18), very similar
numbers to those obtained in our research.
The cause of death in 9 patients was tumor relapse
(32% in this group). The second cause of decease was vi-
ral relapse, due especially to the C-virus. These data are
similar to those published by other authors (19). 
The incidence of previously unknown HCC (incidental
HCC) is quite variable. It depends on the bibliography
and it oscillates between 15 and 50% (19-22). In the sam-
ple of our hospital it has been 32,1%. In spite of being de-
scribed as a lower survival for incidental HCC patients,
this condition has not been proved significant in the uni-
variate and multivariate analyses.
Patients with tumor relapse see their survival drastical-
ly reduced. The univariate analysis reveals three parame-
ters associated to this complication: the microscopic vas-
cular invasion, the size of the nodules and the histological
differentiation. These variables have been already validat-
ed and cited as risk factors by other authors (13,19, 23-25).
In the multivariate analysis, only the size of the nodules
and the vascular invasion have been proved to be indepen-
dent risk factors, as some other authors have already said
(13,19,23,26). The microscopic vascular invasion is a
high risk factor of tumor relapse. It has been associated to
the decrease of survival and must be considered as a key
element in the development of strategies that prevent re-
lapse after the transplant (26). In fact, some studies have
been aimed to find markers that help in selecting patients
with a high risk of vascular invasion (27).
The size of the nodules has been considered by some
authors as a way to predict relapse and survival (28,29),
yet in other groups it has not been possible to establish
this relationship, partly due to problems of sample size
(13,30). It must be taken into account that the size of the
nodules analyzed in this study was obtained from the ex-
plant. This increases the accuracy of the analysis of the
interaction between size and risk of relapse, but its value
remains aside due to the discrepancies about the image
techniques, in which the tumor stages are generally un-
derestimated. 
To sum up, the results of this study prove that with the
current criteria for selecting candidates the tumor relapse
is not very frequent. The microscopic vascular invasion
and the size of the nodules allow predicting reliably a
higher risk of recurrence. This group of patients with bad
prognosis can take benefit from more suitable guidelines
of immunosuppression within the frame of controlled
clinic studies and a more intensive clinic monitoring. 
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